Hüning S, von Dücker L, Kohl W K, Nashan D
Hautklinik, Klinikum Dortmund gGmbH, Beurhausstr. 40, 44137, Dortmund, Deutschland.
Klinik für Dermatologie, Allergologie und Venerologie, Universität zu Lübeck, Lübeck, Deutschland.
Hautarzt. 2019 Aug;70(8):645-656. doi: 10.1007/s00105-019-4446-0.
Herpes zoster (HZ) is caused by the reactivation of varicella zoster virus. The incidence of herpes zoster and associated problems increases with age. With a life-long prevalence of 30%, every second 85-year-old person experiences HZ once in his lifetime. Three therapeutic columns are based on antiviral, topical and analgetic therapies. An extreme handicap is acute and persistent pain which can develop into postherpetic neuralgia (PHN). Those pain symptoms are predominantly neuropathic. The management of acute and chronic manifestation of pain may be challenging. HZ vaccination represents a substantial improvement in terms of prevention of herpes zoster and reduction of long-term complications, such as PHN. The permanent vaccination commission of the Robert Koch Institute recommends vaccination with dead virus for all persons over the age of 60 years. Risk groups like immunosuppressed patients are advised to be vaccinated starting at the age of 50 years.
带状疱疹(HZ)由水痘-带状疱疹病毒的再激活引起。带状疱疹及其相关问题的发病率随年龄增长而增加。其终身患病率为30%,每两个85岁的人中就有一人一生中会经历一次带状疱疹。三种治疗方法基于抗病毒、局部和镇痛疗法。一个极端的障碍是急性和持续性疼痛,它可能发展为带状疱疹后神经痛(PHN)。这些疼痛症状主要是神经性的。疼痛的急性和慢性表现的管理可能具有挑战性。带状疱疹疫苗接种在预防带状疱疹和减少长期并发症(如带状疱疹后神经痛)方面有显著改善。罗伯特·科赫研究所的常设疫苗接种委员会建议60岁以上的所有人接种灭活病毒疫苗。免疫抑制患者等风险群体建议从50岁开始接种疫苗。